Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro

Fig. 5

BV2 cell treatment with MSC-CM. Concentrations of human IL-6 (a, **p < 0.01 primed vs unprimed), TNF-α (b), G-CSF (c) and IL-10 (d) were measured in the CM of MSCs (n = 4 experiments). ELISAs to detect mouse isoforms of the same molecules (e, f, g, and h, respectively, n = 4 experiments) showed that the addition of MSC-CM induced significant changes in their secretion (when compared with LPS-treated BV2 cells). CM from IL-1α-primed MSCs induced a stronger response, evidenced by a larger reduction in the secretion of IL-6 (p < 0.001) and TNF-α (p < 0.05) and by an increased secretion of IL-10. Note that most IL-10 values are below the quantification limit of the assay (dashed line), so statistical analysis cannot be performed with these values. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001. G-CSF granulocyte-colony stimulating factor, hMSC human mesenchymal stem/stromal cell, IFN-γ interferon gamma, IL interleukin, IL-1Ra interleukin-1 receptor antagonist, LPS lipopolysaccharide, nd not detectable, TNF-α tumour necrosis factor alpha

Back to article page